PTC/SB/08s (08-03 ) Approved for use through 07/31/2008, OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

> Remove Pages, Columns, Lines where

Relevant Passages or Relevant

to a collection of information unless it contains a valid OMB control number. Application Number 10505024

Code<sup>1</sup> Issue Date

Examiner Cite Patent Number

No

	Application Number		10595024		
	Filing Date		2005-12-20		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Mitsu		uru SEKIYA		
( Not for submission under 37 CFR 1.99)	Art Unit				
( Not for Submission under or of it 1.00)	Examiner Name				
	Attorney Docket Number	er e	44471/324299		

U.S.PATENTS

Name of Patentee or Applicant

of cited Document

Initial*	No	Patent Number	Code <sup>1</sup>	ISSUE L	Jate				Appear	ges or relev	/ant
	1	5532585		1996-0	7-02	Oudet et al.					
If you wish	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where ges or Relev	
	1	20030137293		2003-0	7-24	Welsch et al.					
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button	Add		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country	y Code <sup>2</sup>	Kind Code4	Publication Date	Name of Patente Applicant of cited Document	or (	vhere Rel	or Relevant	74
	1	JP2003315088	JP			2003-11-06	Robert Bosch Gmb	Н			Z
	2	JP7500421	JP			1995-01-12	Moving Magnet Technologies S.A.				Z
	3	JP200328605	JP			2003-01-29	Mitsubishi Electric	Corp.			<b>V</b>

			Applic	Application Number			10595024				
			Filing	Filing Date			2005-12-20				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		First N	First Named Inventor Mitsur			uru SEKIYA					
		Art Unit						_			
	(Not for Submission under 37 OFK 1.33)		Exami	Examiner Name							
		Attorney Docket Number			r	44471/324299					
											_
		_		т—		_		_			-
		4	JP5984404	JP			1984-06-07		Nissin Kohki Kabushiki Kaisha		

	5	JP200174409	JP		2001-03-23	Mikura Corp.		ℤ
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
NON-PATENT LITERATURE DOCUMENTS Remove								

		NON-PATENT LITERATURE DOCUMENTS Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.	Τŧ

EXAMINER SIGNATURE

Examiner Signature

Date Considered

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you wish to add additional non-patent literature document citation information please click the Add button

See for Codes of USPTO Patent Documents at twee USPTO\_GOLV or MPEP 66104. Takes on this hall assed the document, by the involved on (WPD)
Standard 513, 1 \*\*Cuplanese patent documents, the exclusion of the year of the register or present set serial runber of the patent document,
\*\*Yard of document by the appropriate symbols as endicated on the document under WIPO Standard ST.16 if possible, \*\*Applicant is to place a check mark here if
\*\*English targough stritation in altitude.\*\*

	Application Number		10595024	
	Filing Date		2005-12-20	
DRMATION DISCLOSURE	First Named Inventor Mitsu		uru SEKIYA	
for submission under 37 CFR 1.99)	Art Unit			
,	Examiner Name			
	Attorney Docket Number		44471/324299	

### CERTIFICATION STATEMENT

Please see 37	OFD 4 07				161	٠.
Please see 3/	CFR 1.97	and 1.90 to	make the	appropriate	selection(	SJ.

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

## OR

STA (Not

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patter office in a counterpart foreign apatter inconsideration, and, to the knowledge of the person signing the certification after making measonable inclusiv, no item of information contained in the information disclosure statement was shrown to any individual designated in 37 OFR 1.56(c) more than three months prior to the filing of the information disclosure.

# 7 See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

### None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Brenda O. Holmes 6799/	Date (YYYY-MM-DD)	2005-12-20
Name/Print	Brenda O. Holmes	Registration Number	40339

This collection of information is required by 37 CFR. 187 and 1.98. The information is required to obtain or retain a benefit by the public which is to lie (and by the USFTO to process) an application. Confidentially is generate by \$5.U.S. CI 20 and 37 CFR. 11.4. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. Operatment of Commence, P. O. Box 1450, Alexandrin, V.S. 2231-1450. DN OTS END FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, VA 2231-1450.

#### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) (2) famishing of the information solicide is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademan Kolline is to process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission, which may related the process and/or examines your submission, which may related the process and/or examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
  - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.